ProCE Banner Activity

ECHELON-2: Phase III Trial of Brentuximab Vedotin + CHP vs CHOP in Previously Untreated CD30+ Peripheral T-Cell Lymphomas

Slideset Download
Conference Coverage
Frontline BV + CHP achieved superior PFS and OS vs standard CHOP with a manageable safety profile, leading to the recent FDA approval in this setting.

Released: December 11, 2018

Expiration: December 10, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology